Clinical trials: Lung Tumors
Lung Cancer
Multimodal Prehabilitation in Thoracic Surgery
This trial aims to assess the impact of a multimodal prehabilitation program in high-risk patients undergoing lung resection surgery.
- Trial name
- NCT04052100
- Testing
- Usual care, Multimodal prehabilitation
- Where
- Spain
- Volunteers
- 158 people
- Sponsor
- Hospital Clinic of Barcelona
Non-small Cell Lung Cancer
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated.
- Trial name
- NCT00516100
- Testing
- bortezomib
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aptium Oncology Research Network
Non-small Cell Lung Cancer Stage III
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
Standard treatment for stage III Non-Small Cells Lung Cancer (NSCLC) not eligibile for surgery is concomitant chemoradiotherapy.
- Trial name
- BRIDGE (NCT04765709)
- Testing
- durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously…
- Trial name
- reICB (NCT07130032)
- Testing
- reICB regimen (NSCLC), reICB regimen (melanoma)
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- EuroCityClinic LLC
Cancer
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
The investigators performed a multi-centered, randomized, double blinded, placebo-controlled, prospective clinical trial on the effect of Yiqi-yangyin-jiedu decoction (YYJD), a chinese herbal medicine (CHM) formula combined with…
- Trial name
- NCT02929693
- Testing
- gefitinib, Yiqi-yangyin-jiedu decoction
- Volunteers
- 198 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Lung Neoplasms, Esophagitis
Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy
The investigators conducted this phase II study of EGCG therapy protection of the esophagus from damage induced by radiotherapy.
- Conditions
- Lung Neoplasms, Esophagitis, Prevention & Control, Epigallocatechin Gallate
- Trial name
- NCT02577393
- Testing
- EGCG, mLDG
- Volunteers
- 83 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non-small Cell Lung Cancer
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments.
- Trial name
- NCT07382726
- Testing
- Adagrasib, Iza-bren
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Non-small Cell Lung Cancer
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell…
- Trial name
- neoSCORE Ⅱ (NCT05429463)
- Testing
- Sintilimab, Carboplatin, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-small Cell Lung Cancer
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the benefit of adding suramin at a non-cytotoxic dose to carboplatin and docetaxel regimen in the treatment of chemo-naïve patients with non-small cell lung cancer.
- Trial name
- NCT01038752
- Testing
- Suramin Drug:Docetaxel Drug: Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Optimum Therapeutics, LLC
Non Small Cell Lung Cancer
Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
Modern anti-cancer treatments are focused on development of molecular based therapies i.e. specific treatments targeted against underlying biological processes.
- Trial name
- NCT01596452
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Non Small Cell Lung Cancer
Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients
This is an epidemiological,multicenter study of genomic and expression profiles of patients with newly diagnosed NSCLC.Two hundred and fifty NSCLC patients who fulfill the criteria are to be recruited by investigational…
- Trial name
- CHOICE (NCT02113852)
- Volunteers
- 250 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer, Nonsmall Cell
Pulmonary Function After Arterial Sleeve Lobectomy
Lung cancer is the leading cause of cancer death worldwide. Despite the evolution of medical and multimodal treatments, surgical treatment remains the curative management in the localized cancer.
- Trial name
- NCT04981938
- Testing
- Lobectomy with pulmonary artery reconstruction
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Centre Hospitalier Régional Universitaire Montpellier
Lung Cancer, Nonsmall Cell
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC).
- Trial name
- FL-ALTER (NCT04028778)
- Testing
- Gefitinib, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Non-Small Cell Lung Cancer
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to durvalumab will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT02673814
- Testing
- durvalumab, bavituximab
- Sponsor
- Peregrine Pharmaceuticals
Non-small Cell Lung Cancer
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
- Trial name
- CHORUS (NCT04905316)
- Testing
- Canakinumab, Durvalumab, Radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate local disease control after 2 years in patients with non-metastatic, non-operated non-small-cell lung cancer treated by radiotherapy.
- Trial name
- SBRT-NSCLC (NCT00870116)
- Testing
- SBRT by cyberknife, SBRT by linear accelerator, Conformational radiotherapy
- Where
- 9 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Leon Berard
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer
The objective of this trial is to assess the safety and feasibility of delivering SBRT to patients with limited BMs (less than 10 lesions of lung cancer) by establishing the maximally tolerated dose (MTD) of SABR in 5 fractions.
- Conditions
- Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Brain Metastases
- Trial name
- NCT05588206
- Testing
- Hypofractionated Stereotactic Radiotherap
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First People's Hospital of Hangzhou
Anxiety, Evidence-based Practice
The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer
This randomized controlled trial evaluated the effects of a 7-day self-selected music intervention on caregiver burden and anxiety among first-degree family caregivers of patients with lung cancer.
- Conditions
- Anxiety, Evidence-based Practice, Caregiver Burden, Nursing
- Trial name
- NCT07847138
- Testing
- Music intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Izmir Bakircay University
Advanced Oligometastatic Non-small Cell Lung Cancer
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04306926
- Testing
- TQB2450, SBRT
- Where
- 4 sites in China
- Volunteers
- 59 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.